Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PARKINSON DISEASE

Apomorphine infusion in advanced Parkinson disease

The TOLEDO study provides new evidence to support the use of subcutaneous apomorphine infusion to control motor fluctuations in patients with advanced Parkinson disease. The findings should encourage neurologists to consider implementing apomorphine infusion or other device-aided therapies earlier in the disease course, before the emergence of troublesome dyskinesias.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Parkinson disease progression and therapy.

References

  1. Antonini, A. et al. Medical and surgical management of advanced Parkinson’s disease. Mov. Disord. 33, 900–908 (2018).

    Article  Google Scholar 

  2. Antonini, A. et al. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson’s disease. CNS Drugs 24, 119–129 (2010).

    Article  CAS  Google Scholar 

  3. Iravani, M. M., McCreary, A. C. & Jenner, P. Striatal plasticity in Parkinson’s disease and L-dopa induced dyskinesia. Parkinsonism Relat. Disord. 18, S123–S125 (2012).

    Article  Google Scholar 

  4. Jenner, P. Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson’s disease. Neurol. Clin. 31, S17–S35 (2013).

    Article  Google Scholar 

  5. Katzenschlager, R. et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 17, 749–759 (2018).

    Article  CAS  Google Scholar 

  6. Olanow, C. W. et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 13, 141–149 (2014).

    Article  CAS  Google Scholar 

  7. Antonini, A. et al. Effect of levodopa–carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients. Mov. Disord. 31, 530–537 (2016).

    Article  CAS  Google Scholar 

  8. Schuepbach, W. M. et al. Neurostimulation for Parkinson’s disease with early motor complications. N. Engl. J. Med. 368, 610–622 (2013).

    Article  CAS  Google Scholar 

  9. Dafsari, H. S. et al. Subthalamic stimulation improves quality of life of patients aged 61 years or older with short duration of Parkinson’s disease. Neuromodulation 21, 532–540 (2018).

    Article  Google Scholar 

  10. Antonini, A. et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr. Med. Res. Opin. https://doi.org/10.1080/03007995.2018.1502165 (2018).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank SciMentum, San Francisco, CA, USA for their help with drawing the figure.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Angelo Antonini.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antonini, A., Jenner, P. Apomorphine infusion in advanced Parkinson disease. Nat Rev Neurol 14, 693–694 (2018). https://doi.org/10.1038/s41582-018-0083-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-018-0083-y

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing